All lobbying filings

Michael Best Strategies LLC

Michael Best Strategies LLC filed a Q2 termination report for Sarepta Therapeutics on July 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Sarepta Therapeutics · Medical research and drug development company

As filed: MICHAEL BEST STRATEGIES LLC for SAREPTA THERAPEUTICS.

All filings by Michael Best Strategies LLC · Everything Sarepta Therapeutics has reported

Filing · LD-2 quarterly report Q2 termination

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Representation ended

May 12, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

Medical/Disease Research/Clinical Labs

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.